Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $2000.0.

  • Ironwood Pharmaceuticals' Capital Expenditures fell 8750.0% to $2000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $35000.0, marking a year-over-year decrease of 9008.5%. This contributed to the annual value of $142000.0 for FY2024, which is 4798.53% down from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' Capital Expenditures is $2000.0, which was down 8750.0% from $2000.0 recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Capital Expenditures high stood at $211000.0 for Q4 2023, and its period low was -$27000.0 during Q4 2022.
  • Moreover, its 5-year median value for Capital Expenditures was $40000.0 (2023), whereas its average is $51000.0.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Capital Expenditures tumbled by 12109.38% in 2022, and later skyrocketed by 88148.15% in 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Capital Expenditures (Quarter) stood at $128000.0 in 2021, then crashed by 121.09% to -$27000.0 in 2022, then skyrocketed by 881.48% to $211000.0 in 2023, then plummeted by 92.42% to $16000.0 in 2024, then crashed by 87.5% to $2000.0 in 2025.
  • Its last three reported values are $2000.0 in Q3 2025, $2000.0 for Q2 2025, and $31000.0 during Q1 2025.